Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer

Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer

Cheng-Yu Chang,1,* Chung-Yu Chen,2,3,* Shih-Chieh Chang,4– 6,* Yi-Chun Lai,4,5 Yu-Feng Wei7– 9 1Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; 2Department of Internal Medicine, National Taiwan University Ho...

Full description

Bibliographic Details
Main Authors: Chang CY, Chen CY, Chang SC, Lai YC, Wei YF
Format: Article
Language:English
Published: Dove Medical Press 2021-09-01
Series:Cancer Management and Research
Subjects:
older adults
epidermal growth factor receptor tyrosine kinase inhibitor
non-small-cell lung cancer
performance status
Online Access:https://www.dovepress.com/efficacy-and-prognosis-of-first-line-egfr-tyrosine-kinase-inhibitor-tr-peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/efficacy-and-prognosis-of-first-line-egfr-tyrosine-kinase-inhibitor-tr-peer-reviewed-fulltext-article-CMAR

Similar Items